FDA-approved weight loss options Weekly GLP-1 medications: Mounjaro (tirzepatide): 16-22% weight loss Wegovy (semaglutide): Typically, 15% weight loss Zepbound (tirzepatide): Often 20-23% weight loss Why starting GLP-1s now makes sense Obesity increases risks for type 2 diabetes, heart failure, cardiovascular disease, and other serious conditions
We disclaim all liability for actions you take or fail to take based on any content of this article.
Many patients are surprised to learn that pre-operative medical tests, such as blood work, imaging studies, or cardiac evaluations, may be recommended to ensure you are a safe candidate for surgery
ARBs prevent angiotensin II from interacting with the AT1R, which stops its vasoconstrictive and aldosterone-stimulating actions
Semaglutide acts solely as a GLP-1 receptor agonist
Takeaway: Collagen supports tissue building blocks, while BPC-157 is proposed to influence healing signals directly
